Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 4 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.
30 May 2017
Pain is a multidimensional experience that often requires a combination of various approaches to bring about optimal outcomes. At a recent scientific symposium held during the 7th Association of South-East Asian Pain Societies Congress held in Yangon, Myanmar, Professor Stefano Coaccioli discussed the evolution of ns-NSAIDs and how dexketoprofen trometamol (Ketesse®; A. Menarini) can improve acute pain management.

PPI effectively attenuates acid-related dyspepsia

29 Jun 2019

Monotherapy with a proton pump inhibitor appears to be effective in the treatment of functional dyspepsia (FD) symptoms associated with gastro-oesophageal reflux disease (GERD), according to a study.

The study included 233 patients (mean age, 56.5 years; 58 percent male; mean body mass index, 23.7 kg/m2) with FD and GERD, among whom 40 had mild, 151 had moderate and 42 had severe GERD symptoms. All patients were given PPI treatment for 4 weeks after endoscopy, and the severity of the symptoms and responses to treatment were evaluated prior to and after 4 weeks of treatment using the Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test (GERD-TEST).

In the entire population, the pretreatment scores for the symptoms recorded were as follows: 3.7 for GERD-symptom subscale (SS), 3.3 for FD-SS, 3.6 for FD-epigastric pain syndrome symptom, and 3.0 for FD-postprandial distress-SS.

Analysis of the pretreatment scores for each symptom showed that a higher GERD-SS score was significantly associated with higher scores on any kind of FD score.

Furthermore, 4 weeks of PPI treatment led to a significant reduction in any of GERD/FD symptoms. Changes in the score for each symptom were markedly greater in the group of patients with more severe GERD-SS.

In light of the present data, PPI monotherapy may be considered the treatment of choice in patients with FD and more severe GERD symptom, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 4 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.
30 May 2017
Pain is a multidimensional experience that often requires a combination of various approaches to bring about optimal outcomes. At a recent scientific symposium held during the 7th Association of South-East Asian Pain Societies Congress held in Yangon, Myanmar, Professor Stefano Coaccioli discussed the evolution of ns-NSAIDs and how dexketoprofen trometamol (Ketesse®; A. Menarini) can improve acute pain management.